HomeMolecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12) Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Featured Products

E1051 MRTX1133 MRTX1133 is a highly selective inhibitor of mutant KRAS G12D and can reversibly binds to the activated and inactivated KRAS G12D mutants and inhibit their activity. The specificity of MRTX1133 to KRAS G12D is more than 1000 times that of wild-type KRAS.
E1207 Osunprotafib (ABBV-CLS-484) Osunprotafib (ABBV-CLS-484) is a potent PTPN1 or PTPN2 inhibitor with a sub-nanomolar activity.
E1349 Ralometostat (TNG908) Ralometostat (TNG908) is a potent, selective, and brain-penetrant inhibitor of PRMT5 with an IC50 of 4 μM, acting through an MTA-cooperative mechanism. It also shows antitumor activity in a xenograft model.
E1490 IAG933 IAG933 (YAP-TEAD-IN-3) is a small molecule and acts as a YAP/TAZ-TEAD inhibitor. It also inhibits NCI-H2052 and can be used in research of tumor invasion and metastatic spread of solid tumors.
E1563 GNE-7883 GNE-7883 is a potent and allosteric small-molecule inhibitor of pan-TEAD, that allosterically blocks the interactions between YAP/TAZ and all human TEAD paralogs through binding to the TEAD lipid pocket. It effectively reduces chromatin accessibility at TEAD motifs, suppresses cell proliferation in a variety of cell line models and achieves strong antitumor efficacy in vivo. Furthermore, it effectively overcomes KRAS G12C inhibitor resistance.
E1858 RMC-7977 RMC-7977 is a potent, reversible, tri-complex oral inhibitor that selectively targets active (GTP-bound) forms of KRAS, HRAS, and NRAS, which exhibits broad-spectrum activity against both mutant and wild-type variants (a RASMULTI (ON) inhibitor). It also exhibits significant anti-tumor efficacy in pancreatic ductal adenocarcinoma (PDAC).
E1962 Zoldonrasib (RMC-9805) Zoldonrasib (RMC-9805) is an orally active inhibitor of KRAS G12D. RMC-9805 inhibits RAS signaling, leading to apoptosis in cancer cells with the KRAS G12D mutation.
E6486 VT3989 VT3989 (YAP/TAZ inhibitor-3) is a potent and selective oral inhibitor of TEAD auto-palmitoylation, blocking its interaction with yes-associated protein (YAP). It exhibits antitumor activity and shows potential for treating mesothelioma and solid tumors with NF2 mutations.
S1001 Navitoclax (ABT-263) Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
S1036 PD0325901 (Mirdametinib) Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
S1049 Y-27632 Dihydrochloride Y-27632 2HCl is a selective ROCK1 and ROCK2 inhibitor with a Ki of 140 nM and 300nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
S1067 SB431542 SB431542 is a potent and selective inhibitor of ALK5 with IC50 of 94 nM in a cell-free assay, 100-fold more selective for ALK5 than p38 MAPK and other kinases.
S1208 Doxorubicin (Adriamycin) Hydrochloride Doxorubicin Hydrochloride is an antibiotic agent and DNA Topoisomerase II Inhibitor with IC50 of 2.67 μM against human DNA topoisomerase II. This compound reduces basal phosphorylation of AMPK and is used in the concomitant treatment of HIV-infected patients but is found to be at high risk of HBV reactivation. This product may precipitate when dissolved in PBS solution. It is recommended to prepare the stock solution in pure water and dilute with either pure water or saline to obtain the working solution. It can be used to induce animal models of kidney disease.
S1237 TMZ(Temozolomide) TMZ(Temozolomide) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.
S1263 CHIR-99021 (Laduviglusib) Laduviglusib (CHIR-99021, CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
S1413 Bafilomycin A1 (Baf-A1) Bafilomycin A1(Baf-A1) is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM. Bafilomycin A1 is found to inhibit autophagy while induces apoptosis.
S1421 Staurosporine (STS) Staurosporine (STS) is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
S1459 Thiazovivin (TZV) Thiazovivin is a novel ROCK inhibitor with IC50 of 0.5 μM in a cell-free assay, promotes hESC survival after single-cell dissociation.
S2449 Forskolin (Colforsin) Forskolin (Colforsin) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.
S2619 MG132 MG132 ((S,R,S)-(-)-MG132, Z-Leu-D-Leu-Leu-al) is a potent proteasome (ChTL, TL, and PGPH) inhibitor. MG132 also inhibits calpain (IC50=1.2 μM). MG132 can be used to induce animal models of Parkinson’s disease.
S2684 CX-5461 (Pidnarulex) Pidnarulex (CX-5461) is an inhibitor of rRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA with IC50 of 142 nM in HCT-116, A375, and MIA PaCa-2 cells, has no effect on Pol II, and possesses 250- to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation.
S2759 Fimepinostat (CUDC-907) CUDC-907 is a dual PI3K and HDAC inhibitor for PI3Kα and HDAC1/2/3/10 with IC50 of 19 nM and 1.7 nM/5 nM/1.8 nM/2.8 nM, respectively. CUDC-907 induces cell cycle arrest and apoptosis in breast cancer cells. Phase 1.
S2924 Laduviglusib (CHIR-99021) Hydrochloride Laduviglusib (CHIR-99021; CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
S4592 SBE-β-CD SBE-β-CD is a novel, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.
S6704 PEG300 PEG300 (Polyethylene glycol 300) is a water-miscible polyether widely used in biochemistry, structural biology, and medicine in addition to pharmaceutical and chemical industries. It serves as a kind of solubilizer, excipient, lubricant, and chemical reagent. PEG300 helps in the formation of hydrogels in situ upon mixing with silk. These PEG–silk hydrogels are of interest for many biomedical applications, such as anti-fouling and anti-adhesion.
S6723 Darovasertib (LXS196) Darovasertib (LXS-196, IDE-196) is a selective inhibitor of protein kinase C (PKC).
S7023 Z-VAD-FMK Z-VAD-FMK (Z-VAD(OMe)-FMK) is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
S7037 Wnt-C59 (C59) Wnt-C59 (C59) is a PORCN inhibitor for Wnt3A-mediated activation of a multimerized TCF-binding site driving luciferase with IC50 of 74 pM in HEK293 cells.
S7048 BMN-673 (Talazoparib) Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.
S7086 IWR-1-endo IWR-1-endo (endo-IWR 1, IWR-1) is a Wnt pathway inhibitor with IC50 of 180 nM in L-cells expressing Wnt3A, induces Axin2 protein levels and promotes β-catenin phosphorylation by stabilizing Axin-scaffolded destruction complexes.
S7099 (-)-Blebbistatin (-)-Blebbistatin ((S)-(-)-Blebbistatin) is a cell-permeable inhibitor for non muscle myosin II ATPase with IC50 of ~2 μM in cell-free assays, does not inhibit myosin light chain kinase, inhibits contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly.
S7128 EPZ-6438 (Tazemetostat) Tazemetostat (EPZ-6438, E7438) is a potent, and selective EZH2 inhibitor with Ki and IC50 of 2.5 nM and 11 nM in cell-free assays, exhibiting a 35-fold selectivity versus EZH1 and >4,500-fold selectivity relative to 14 other HMTs.
S7223 RepSox (E-616452) RepSox (E-616452, SJN 2511, ALK5 Inhibitor II) is a potent and selective inhibitor of the TGFβR-1/ALK5 with IC50 of 23 nM and 4 nM for ATP binding to ALK5 and ALK5 autophosphorylation in cell-free assays, respectively.
S7242 Erastin Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS. Solutions are unstable and should be fresh-prepared.
S7297 AZD9291 (Osimertinib) Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
S7530 Vactosertib (TEW-7197) Vactosertib  (TEW-7197, EW-7197) is a highly potent, selective, and orally bioavailable TGF-β receptor ALK4/ALK5 inhibitor with IC50 of 13 nM and 11 nM, respectively. Phase 1.
S7655 Telaglenastat (CB-839) Telaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.
S7693 Ceralasertib (AZD6738) Ceralasertib (AZD6738) is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.
S7699 Liproxstatin-1 Liproxstatin-1 is a potent ferroptosis inhibitor with an IC50 of 22 nM.
S7766 GSK1265744 (Cabotegravir) Cabotegravir (GSK744, GSK1265744, S/GSK1265744) is a long-acting HIV integrase inhibitor against a broad range of HIV subtypes, and inhibits the HIV-1 integrase catalyzed strand transfer reaction with IC50 of 3.0 nM. Phase 2.
S7775 Emricasan (IDN-6556) Emricasan (IDN-6556, PF 03491390, PF-03491390) is a potent irreversible pan-caspase inhibitor. Emricasan is an inhibitor of Zika virus infection.
S7853 Pelabresib (CPI-0610) Pelabresib (CPI-0610) is a potent and selective benzoisoxazoloazepine BET bromodomain inhibitor with an IC50 of 39 nM for BRD4-BD1 in TR-FRET assay and currently undergoing human clinical trials for hematological malignancies. CPI-0610 inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes.
S7858 Dibutyryl cAMP (db cAMP/Bucladesine) sodium Bucladesine sodium is a cell-permeable PKA activator by mimicing the action of endogenous cAMP. Dibutyryl-cAMP (Bucladesine) is also a phosphodiesterase (PDE) inhibitor.
S8048 ABT-199 (Venetoclax) Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.
S8067 Vorapaxar (MK-5348) Vorapaxar (SCH 530348, MK-5348) is a potent and orally active thrombin receptor (PAR-1) antagonist with Ki of 8.1 nM.
S8586 Nedisertib (M3814) Nedisertib (M3814, Peposertib, MSC2490484A) is an orally bioavailable, highly potent and selective inhibitor of DNA activated protein kinase (DNA-PK) with IC50 of < 3 nM.
S8668 GDC-0077 (Inavolisib) Inavolisib (GDC-0077, RG6114, RO-7113755) is a potent selective inhibitor of PI3K alpha (PI3Kα) with an IC50 of 0.038 nM. GDC-0077 is >300-fold more selective for PI3K alpha over the other class I PI3K isoforms (beta, delta, and gamma) and >2000-fold more selective over PIK family members. GDC-0077 binds to the ATP binding site of PI3K and inhibits the phosphorylation of PIP2 to PIP3.
S8879 BMS-986165 (Deucravacitinib) Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases.
S8960 CD38 inhibitor 1 (compound 78c) CD38 inhibitor 1 (compound 78c, CD38-IN-78c, MDK-7553) is a potent inhibitor of CD38 with IC50 of 7.3 nM and 1.9 nM for human CD38 and mouse CD38, respetively.
S8994 Zotatifin (eFT226) Zotatifin (eFT226) is a highly effective and sequence-selective inhibitor of the RNA helicase eIF4A. It promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5'-UTRs, with an IC50 of 2 nM, and disrupts the assembly of the eIF4F initiation complex. By enhancing the interaction between eIF4A and polypurine RNA sequence or structural motifs, zotatifin converts eIF4A into a sequence-specific translation repressor, thereby regulating the translation of certain target genes. It also exhibits anti-tumor activity.

New Products

Click to View More
A2177 Anti-mouse IFNγR (CD119)-Invivo Anti-mouse IFNγR (CD119)-Invivo reacts with the mouse IFNγR (interferon gamma receptor) α chain also known as CD119 and IFNγ receptor 1. CD119 heterodimerizes with IFNγ receptor 2 (AF-1) to form the IFNγR, a Class II cytokine receptor.
A2178 Anti-mouse/human IL-5-Invivo Anti-mouse/human IL-5-Invivo reacts with mouse and human interleukin-5 (IL-5), a 26 kDa homodimeric cytokine. IL-5 stimulates B lymphocyte differentiation and proliferation and increases the secretion of IgM and IgA.
A2176 Anti-mouse CD8α (53-6.7)-Invivo Anti-mouse CD8α (53-6.7)-Invivo reacts with mouse CD8α. The CD8 antigen is a transmembrane glycoprotein that acts as a co-receptor for the T cell receptor (TCR).
F0040 CD11b Antibody [F15D4] CD11b,CD11b/ITGAM,Integrin alphaM [CD11b],Integrin αM/CD11b,ITGAM
F0147 N-Cadherin Antibody [G6B2] CD325,CD325 (N-Cadherin),N Cadherin,N-Cadherin
F1470 CGRP Antibody [N20P10] Calcitonin Gene Related Peptide,Calcitonin Gene-Related Peptide,CGRP
F3008 C/EBPβ Antibody [B2A6] C/EBP β,C/EBPβ,C/EBPβ (LAP),CEBP Beta
F0428 Cas9 (S. pyogenes) Antibody [L14C20] Cas9,CRISPR-Cas9
F0647 Phospho-FGF Receptor (Tyr653/654) Antibody [F13P7] FGFR1 (phospho Y653),Phospho-FGF Receptor (Tyr653/654),Phospho-FGF Receptor 1 (Tyr653/654)
P1269 Pegcetacoplan acetate Pegcetacoplan acetate, a PEGylated cyclic peptide, is the first approved inhibitor of complement component C3/C3b designed to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). It binds C3 and C3b to inhibit convertase-mediated C3 cleavage, blocking C3b opsonization (extravascular hemolysis) and downstream MAC formation (intravascular hemolysis).
E8319 Ro 48-8071 fumarate Ro 48-8071 fumarate is a potent, selective inhibitor of 2,3-oxidosqualene cyclase (OSC) (IC50 = 6.5 nM), a key enzyme downstream of HMG-CoA reductase that catalyzes lanosterol formation in cholesterol biosynthesis. It reduces intracellular cholesterol levels without the feedback upregulation of HMG-CoA reductase seen with statins, providing a distinct, self-limiting regulatory loop for lowering LDL-C. Additionally, it also exhibits significant anti-cancer properties by inducing apoptosis and disrupting cell signaling in cancer models.
F2133 Integrin αVβ3 Antibody [C22M19] Integrin alpha V beta 3,Integrin alphaVbeta3,Integrin αV/β3/CD51/CD61
F2700 Myelin Proteolipid Protein Antibody [C23K3] Myelin PLP,PLP1
F2799 PLVAP/PV-1 Antibody [E23J22] Panendothelial Cell Antigen,PLVAP,PLVAP/PV-1
F3420 POMC Antibody [B13A5] ACTH,POMC
F3733 Claudin18.2 Antibody [L24N19] Claudin 18,Claudin18.2
F3673 Laminin α5/LAMA5 Antibody [P21J13] LAMA5,Laminin alpha 5/LAMA5,Laminin alpha5
F0550 NMDA Receptor 2B/GluN2B Antibody [K20B17] NMDA Receptor 2B (GluN2B),NMDAR2B,NR2B
F0977 Phospho-BTK (Tyr223) Antibody [H3N9] BTK (phospho Y223),Phospho-Btk (Tyr223)
F3001 Phospho-ErbB3/HER3 (Tyr1289) Antibody [P19F5] ErbB3 / HER3 (phospho Y1289),Phospho-HER3/ErbB3 (Tyr1289)